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The biological properties and characteristics of microglia
in rodents have been widely described, but little is known
about these features in human microglia. Several murine
microglial cell lines are used to investigate neurodegener-
ative and neuroinflammatory conditions; however, the
extrapolation of the results to human conditions is fre-
quently met with criticism because of the possibility of
species-specific differences. This study compares the
effects of oxaliplatin and of oleic acid Gc-protein-derived
macrophage-activating factor (OA-GcMAF) on two micro-
glial cell lines, murine BV-2 cells and human C13NJ cells.
Cell viability, cAMP levels, microglial activation, and vas-
cular endothelial growth factor (VEGF) expression were
evaluated. Our data demonstrate that oxaliplatin induced
a significant decrease in cell viability in BV-2 and in
C13NJ cells and that this effect was not reversed with
OA-GcMAF treatment. The signal transduction pathway
involving cAMP/VEGF was activated after treatment with
oxaliplatin and/or OA-GcMAF in both cell lines. OA-
GcMAF induced a significant increase in microglia activa-
tion, as evidenced by the expression of the B7-2 protein,
in BV-2 as well as in C13NJ cells that was not associated
with a concomitant increase in cell number. Furthermore,
the effects of oxaliplatin and OA-GcMAF on coculture
morphology and apoptosis were evaluated. Oxaliplatin-
induced cell damage and apoptosis were nearly com-
pletely reversed by OA-GcMAF treatment in both BV-2/
SH-SY5Y and C13NJ/SH-SY5Y cocultures. Our data
show that murine and human microglia share common
signal transduction pathways and activation mecha-
nisms, suggesting that the murine BV-2 cell line may
represent an excellent model for studying human micro-
glia. VC 2015 Wiley Periodicals, Inc.
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Resident microglia, known as the “macrophages of
the central nervous system,” may exert both pro- and
anti-inflammatory effects (Romero-Sandoval et al., 2008).
Microglia become activated by recognizing specific
molecular patterns on pathogenic proteins and toxic
debris during infections or nervous tissue injuries
(Nguyen et al., 2002). Growing evidence ascribes some
pathologic effects to glial cells, such as neuronal hyperex-
citability and chronic inflammation induced by several
toxicants and chemotherapeutic agents, including
platinum-based drugs, taxanes, epothilones, and vinca
alkaloids (Wolf et al., 2008). However, increasing num-
bers of studies provide evidence that microglial cells have
many housekeeping functions that are necessary for
healthy neuronal communication and neuroprotection
(Marchand et al., 2005), contributing to a local immune
environment that is beneficial for nearby healthy glial cells
and neurons. Thus, it has been postulated that a delicate
balance between pro- and anti-inflammatory events after
damage is controlled by the finely tuned expression of
“self-associated molecular pattern” and “altered self” pro-
teins in microglia (Griffiths et al., 2007).
The intricacy of microglial biology is becoming
more apparent, leading to a heightened research interest
in this particular cell type. However, although properties
of microglial cells have been well described in rodents, lit-
tle is known about their human counterparts (Torres-Pla-
tas et al., 2014). Presently, many models of microglial cell
lines, including primary cultures and immortalized cell
lines are used to study neuroinflammatory and neurode-
generative phenomena. Quite obviously, the extrapola-
tion of the results obtained in rodent microglial cells to
their human counterparts may be debatable because, in
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theory, the possibility of species-specific differences
cannot be ruled out.
Therefore, this study was undertaken to assess these
putative species-specific differences in the pathophysio-
logical responses of rodent and human microglial cells. In
particular, the focus of this study is to compare the effects
of oxaliplatin, a well-known neurotoxic anticancer agent,
and of oleic acid Gc-protein-derived macrophage-activat-
ing factor (OA-GcMAF), a protein inducing microglia
activation (Morucci et al., 2014), on two microglial cell
lines, murine BV-2 cells and human C13NJ cells, in terms
of cell viability, cAMP levels, microglia activation, and
vascular endothelial growth factor (VEGF) expression.
Oxaliplatin was chosen for its well-studied mechanism of
action and for its toxicity in neurons and glial cells. OA-
GcMAF was chosen because previous findings (Morucci
et al., 2014) have demonstrated that it is possible to
reverse the neuronal damage inflicted by oxaliplatin sig-
nificantly and to preserve neuronal viability, possibly
through a cAMP/VEGF neuroprotective signaling path-
way. To investigate the role of oxaliplatin and OA-
GcMAF in microglial and neuronal signalling further and
to study the interactions between rodent and human cell
types, we developed cocultures of murine microglial
cells/human neurons (BV-2/SH-SY5Y) and human
microglial cells/human neurons (C13NJ/SH-SY5Y). We
evaluated the morphology and apoptosis as consequences
of the treatment with oxaliplatin and OA-GcMAF in
these cocultures.
MATERIALS AND METHODS
BV-2 Cell Line
After successfully immortalizing murine macrophages
from bone marrow via the v-raf/v-myc-carrying retrovirus (J2;
Blasi et al., 1985), the Blasi research group adapted the same
technique to obtain BV-2 microglia cells (Blasi et al., 1985,
1990). To develop this line, microglia were first purified by
adhesion/agitation and then incubated overnight with control
or J2 virus containing supernatants in cell-specific complete
medium. After 3–4 weeks of incubation, proliferating cells
were observed in the infected cultures, whereas noninfected
cultures lost adherence and died (Blasi et al., 1990). The BV-2
cells were assessed for microglial cell markers; 90% tested posi-
tive for nonspecific esterase activity, and all lacked peroxidase
activity. Furthermore, BV-2 cells were positive for macrophage
antigen (MAC)21 and MAC-2 but were negative for MAC-3.
Similarly to primary microglial cells, they were negative for glial
fibrillary acidic protein (GFAP) and galactocerebroside antigens,
which are markers for astrocytes and oligodendrocytes (Bignami
et al., 1972), respectively. Analysis of cytokine secretion
revealed that interleukin (IL)21 increased in a dose-dependent
manner when stimulated with lipopolysaccharide (LPS; Blasi
et al., 1990). Additionally, given that these cells possess phago-
cytic capabilities, it was demonstrated that Ab(1–42) fibrils
stimulated microglia-mediated phagocytosis in a time- and
dose-dependent manner (Kopec and Caroll, 1998). Although
they show similarities to primary microglia, the BV-2 cells do
contain oncogenes that render them different from primary
microglia in some ways. In particular, they show increased pro-
liferation and adhesion and an increased variability of morphol-
ogies (Horvath et al., 2008). The validity of BV-2 cells as a
sufficient substitute for primary microglia has been debated; this
notwithstanding, only a few studies comparing different micro-
glia lines have been published. One such study was conducted
by Horvath et al. (2008), who compared primary rat microglia
with the BV-2 line with regard to activation markers, motility,
and releasable factors, such as nitric oxide (NO) and cytokines.
It was observed that the primary microglia and BV-2 cells both
expressed the ionized calcium binding adaptor molecule 1
(Iba1), a microglial activation marker. Furthermore, upon LPS
stimulation, BV-2 cells secreted less but still substantial amounts
of NO compared with primary microglia (Horvath et al.,
2008). The hypothesis that BV-2-immortalized cells show fea-
tures similar to those of primary microglia, even though they
are not identical, was further examined by Henn et al. (2009).
This group examined the BV-2 cells as an appropriate alterna-
tive to the primary cultures. They found that, in response to
LPS, 90% of genes induced in the BV-2 cells were also induced
in primary microglia; however, the upregulation of genes in the
BV-2 cells was far less pronounced than in primary microglia
(Henn et al., 2009). In summary, for the BV-2 cell line, there
appears to be a trade-off between the magnitude of the stimula-
tory response with the preparation time and technical feasibility
between experiments.
C13NJ Cell Line
Primary cultures of human embryonic spinal cord and
cortex were prepared from 8–10-week-old embryos as
described by Peudenier et al. (1991). The cultures consisted of
neurons, astrocytes, microglial cells, and fibroblasts. Adherent
cells were selected and transfected by lipofection with PAS plas-
mid containing only the SV40 T antigen cDNA. Three weeks
later, foci were independently isolated, expanded, and harvested
for DNA analysis to demonstrate the presence of the integrated
plasmid.
Monoclonal antibodies against CD68/ki-M7, CD68/
EBM11, CD11b/OKM1, 25F9 (a tissue macrophage marker),
and anti-Fc receptors immunostained 64–98% of the trans-
formed cells. These percentages are similar to those observed
with primary microglial cells, with the exception of CD68/
EBM11, which was expressed in only 8% of the primary micro-
glial cells. Two to nineteen percent of the cells, depending on
the cell colony, phagocytized zymosan particles, with a maxi-
mum of 10 particles/cell. More than 95% of cells displayed
nonspecific esterase activity. The cells were not labeled
with anti-CD68/KiM6, -CD14/leuM3, -CD11c/LeuM5,
-MHCII/DR-2, or -CD4/Leu3a antibodies, which are low or
absent on the membranes of primary microglial cells but are
highly expressed on monocytes (control). The cells did not
express class II major histocompatibility complex (MHCII)
antigens spontaneously, but these antigens could be induced
after stimulation of the transformed cells by human recombi-
nant interferon-g. Antigenic characteristics were retained after
35 passages. Finally, the absence of immunostaining with anti-
GFAP or antineurofilament antibodies in the cells indicated the
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absence of transformed astrocytes or neurons. Transformed cells
as well as primary microglial cells produced IL-6.
Thus, the obtained transformed cells showed the macro-
phagic characteristics of adherence, phagocytosis, and intracyto-
plasmic nonspecific esterase activity and expressed several
macrophagic antigens. The pattern of antigenic expression and
cytokine secretion was identical to that of the primary micro-
glial cells used for the transfection. Furthermore, the trans-
formed cells could be activated with subsequent expression of
MHCII antigens and IL-6 production (Peudenier et al., 1991).
In conclusion, the transformed human microglial cells retained
the properties of primary microglial cells, and they represent a
homogeneous cell population that can be cultured indefinitely.
The human microglial C13NJ cell line was kindly donated by
Dr. Jean Mazella (Institut de Pharmacologie Moleculaire et
Cellulaire).
SH-SY5Y Cell Line
The SH-SY5Y human neuron cell line was purchased
from the Istituto Zooprofilattico dell’Emilia e della Romagna
(Brescia, Italy). The SH-SY5Y cell line was chosen because of
its dual role in oncology and neuropharmacology. This cell
line, originally derived from a metastatic bone tumor biopsy
(Kovalevich and Langford, 2013), represents a well-studied
model for studying the effects of anticancer therapies targeted
to neuroblastoma (Du et al., 2012; Sahu et al., 2013). However,
this cell line also represents a valid model for studying the neu-
robiology of neurodegenerative diseases and neuropathies (Di
Cesare Mannelli et al., 2013a), and it has been extensively used
to study the neuroprotective effects of a variety of treatments
(Thapa et al., 2013). The current study exploited these latter
features of SH-SY5Y cells.
Cell Culturing
BV-2 cells were maintained in RPMI 1640 medium sup-
plemented with 10% fetal bovine serum (FBS) and 2 mM L-
glutamine. C13NJ cells were cultured in Dulbecco’s modified
Eagle’s medium (DMEM) supplemented with 10% FBS and
2 mM L-glutamine. SH-SY5Y neurons were maintained in
DMEM/Ham’s F12 supplemented with 10% FBS and 2 mM
L-glutamine. Cells were maintained in a humidified atmos-
phere at 37C in 95% air/5% CO2. The growth media were
changed every 2–3 days. The BV-2/SH-SY5Y and C13NJ/
SH-SY5Y cocultures were maintained in DMEM supple-
mented with 10% FBS and 2 mM L-glutamine. Cell media,
FBS, and L-glutamine were purchased from EuroClone (Milan,
Italy). Before each treatment (see Results for further descrip-
tion), the cell lines were serum starved for 24 hr in the appro-
priate media without FBS (starvation medium). After 24 hr of
starvation, fresh starvation medium containing the stimuli
described below was added for 24 or 48 hr.
Stimuli
Oxaliplatin (Sigma Aldrich, Milan, Italy), was dissolved in
phosphate-buffered saline (PBS) and used at concentrations of 1
mM, 10 mM, 100 mM, 500 mM, and 1 mM. OA-GcMAF was
kindly donated by Immuno Biotech (Guernsey, Channel
Islands). OA-GcMAF was prepared as described elsewhere
(Knyazeva et al., 2008; Morucci et al., 2014). OA-GcMAF
showed a typical dose-dependent effect on all the different cell
lines used to test its efficacy. The 800 pM concentration was
chosen because it was the highest concentration that induced a
positive cellular response just before reaching the plateau doses
and because higher concentrations did not show any additional
effect.
Cell Viability Assay
Cell viability was evaluated by the reduction of a tetrazo-
lium salt, 2-(2-methoxy-4-nitrophenyl)23-(4-nitrophenyl)25-
(2,4-disulf-ophenyl)22H tetrazolium monosodium salt (WST-
8), as an indicator of cellular dehydrogenase activity. BV-2 and
C13NJ microglial cells were seeded into 96-well plates at den-
sities of 3,000 cells/well and 10,000 cells/well, respectively, in
their appropriate complete growth media. Cells were starved
for 24 hr and then treated with different concentrations of oxa-
liplatin and/or OA-GcMAF. Because of the stronger resistance
of C13NJ cells to oxaliplatin-induced damage, the oxaliplatin
concentrations used on this cell line were higher than those
used for the BV-2 cells. Cells were treated with oxaliplatin
alone for 24 hr and with OA-GcMAF alone for 48 hr. When
the neuroprotective effects of OA-GcMAF were investigated,
OA-GcMAF was added to the starvation cell medium 24 hr
before oxaliplatin, which was then added for an additional 24
hr. In this case, OA-GcMAF remained in the culture media for
a total of 48 hr. At the end of each treatment, the media were
replaced with 100 ml fresh starvation media, and 10 ml chromo-
genic substrate (WST-8) was added to each well. After incubat-
ing the wells for 3 hr at 37C, the absorbance was directly
measured at 450 nm (optical density) with a Multiscan FC pho-
tometer (Thermo Scientific, Milan, Italy). Each experimental
point was performed in quintuplicate, and each experiment was
performed three times.
Cell Density and Morphology Evaluation
BV-2 and C13NJ microglial cells were seeded at 30,000
cells/coverslip in their appropriate complete growth media.
Cells were starved for 24 hr and then treated with different
concentrations of oxaliplatin and/or OA-GcMAF for 24 or
48 hr.
At the end of the treatments, the media were removed
and the cells were washed twice with cold PBS. One milliliter
of 0.5% paraformaldehyde was added to each coverslip for 10
min. After two washes with cold PBS, the coverslips were dried
for 1 hr at room temperature and then stained with H&E dye
following a standard procedure. Coverslips were observed
via light microscopy, and images were taken at different magni-
fications with a digital camera (Nikon Coolpix 990; Nikon
Instrument, Milan, Italy). Quantification of cell density was
performed by measuring the cell surface/mm2 in ImageJ (NIH,
http://imagej.nih.gov/ij, 1.47t).
cAMP Assay
The BV-2 and C13NJ microglial cell lines (both at the
density of 4 3 106 cell/well) were plated in Petri dishes in their
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appropriate complete growth media. After 24 hr of starvation,
cells were treated for 25 min with oxaliplatin and/or OA-
GcMAF. Then, the medium was removed and 1.5 ml of HCl
(0.1 M) was added for 20 min to allow cell lysis and phosphodi-
esterase degradation. Cells were collected by scraping, and the
supernatant was obtained by centrifugation at room tempera-
ture for 10 min at 1,800 rpm. A cAMP-competitive ELISA
assay (Thermo Scientific) was performed on the supernatants to
assess cAMP formation in response to different stimuli.
Western Blotting
The BV-2 and C13NJ microglial cell lines (both at the
density of 4 3 106cell/well) were plated in Petri dishes in their
appropriate complete growth media. After 24 hr of starvation,
cells were treated for 24 or 48 hr with oxaliplatin and/or OA-
GcMAF. Then, the medium was removed, and two washes with
PBS were performed before cells were scraped from the surface
of the dishes. The cell suspensions were centrifuged at 1,000 rpm
for 10 min at room temperature. The pellets were treated with
lysis buffer containing protease inhibitors (Sigma Aldrich) for 30
min at 4C, vortexing every 5 min. The homogenates were cen-
trifuged at 4C for 10 min at 12,000 rpm, and the supernatants
were used to evaluate protein concentrations by the Bradford
method. Equal amounts of protein (30 mg) were analyzed on a
12% polyacrylamide gel and then transferred onto nitrocellulose
membrane (Porablot NPC; Macherey-Nagel, Carlo Erba
Reagents, Milano, Italy). After having been blocked for 1 hr at
room temperature with 5% bovine serum albumin in Tris-
buffered saline (TBS) containing 0.1% Tween 20, the blot was
incubated overnight at 4C with primary antibodies for VEGF
and B7-2 (Santa Cruz Biotechnology, Santa Cruz, CA) at 1:250
and 1:1,000 dilutions, respectively. The primary antibody for
Iba1 (Wako Chemicals, Neuss, Germany) was used at a 0.5 mg/
ml concentration. The goat anti-mouse (for VEGF and B7-2)
and goat anti-rabbit (for Iba1) HRP secondary antibodies (Santa
Cruz Biotechnology) were added at a 1:5,000 dilution for 1 hr at
room temperature, and the VEGF, B7-2, and Iba1 proteins were
detected with the Amersham ECL Plus Western blotting detec-
tion reagent (GE Healthcare, EuroClone). Protein expression
levels were then quantified in ImageJ.
RNA Extraction, Gene Expression, and Analysis by
RT-qPCR
RNA was extracted from the C13NJ and BV-2 cell lines
with the RNeasy Mini kit (Qiagen, Milan, Italy) and DNase
treatment, according to the manufacturer’s instructions. RNA
was quantified with a NanoDrop 1000 UV spectrophotometer
(NanoDrop Technologies, Wilmington, DE).
Reverse transcription was performed with 125 ng total
RNA in a final volume of 25 ll containing 500 mM KCl,
0.1 mM EDTA, 100 mM Tris-HCl (pH 8.3), 5.5 mM MgCl2,
500 lM of each dNTP, 2.5 lM random hexamers, 0.4 U/ll
RNase inhibitor, and 1.25 U/ll Multiscribe reverse transcrip-
tase from the TaqMan reverse transcription reagents kit (Life
Technologies, Milan, Italy). The reverse transcription reaction
was carried out at 25C for 10 min, 48C for 30 min, and 95C
for 3 min. For each sample, 12.5 ng cDNA was added to 10 ll
of the PCR mix containing the dedicated primers/probe set
(13) and 13 Universal PCR Master Mix (Life Technologies).
Specific exon-spanning TaqMan gene expression assays (Life
Technologies) were used: VEGF Hs00900055_m1 for human
VEGF, Hs01567026_m1 for human B7-2, Mm01281449_m1
for mouse B7-2, and Mm00444543_m1 for mouse B7-2. 18S
(Eukaryotic 18S rRNA Endogenous Control P.N. 4319413E;
Life Technologies) was used as a housekeeping gene for both
human and mouse cell lines. Samples were subjected to 40
cycles of amplification at 95C for 15 sec and 60C for 60 sec
in the ABI Prism 7900 sequence detector (Life Technologies)
in triplicate. Gene expression analysis was evaluated relative to
the housekeeping gene transcript by using the comparative Cq
method (Livak et al., 2001). To analyze gene expression levels
between treatments within the two cell lines, a t-test was used,
and a P value of at least 0.05 was considered to be statistically
significant. Transcript-level comparisons were performed in
SPSS 17.0 (SPSS Inc., Chicago, IL).
Detection of DNA Fragmentation To Evaluate
Apoptosis
To study apoptosis, DNA integrity in the BV-2/SH-
SY5Y and C13NJ/SHSY5Y cocultures was evaluated with the
DNA fragmentation detection kit (FragEL fragmentation detec-
tion kit, Fluorescent-TdT Enzyme; Calbiochem, Life Technol-
ogy). The principle of the Fluorescein-FragEL method is that
terminal deoxynucleotidyl transferase (TdT) catalyzes the addi-
tion of fluorescein-labeled and unlabeled deoxynucleotides to
the 30-OH ends that are generated by endonucleases during
apoptotic degeneration. SH-SY5Y/BV-2 and SH-SY5Y/
C13NJ cocultures were plated on coverslips in their appropriate
complete growth media; SH-SY5Y and BV-2 cells were seeded
at densities of 100,000 and 10,000 cells, respectively, whereas
SH-SY5Y and C13NJ cells were seeded at densities of 100,000
and 20,000, respectively. After 24 hr of starvation, the cells
were treated with different concentrations of oxaliplatin and/or
OA-GcMAF for 24 or 48 hr. At the end of the treatments, the
medium was removed, and the cells were washed twice with
cold PBS. The cells were first fixed in 0.5% paraformaldehyde
in PBS for 10 min and then permeabilized for 2 min in cold
acetone at room temperature. After three washes in TBS, the
slides were incubated in 13 TdT equilibration buffer for 30
min at room temperature. Next, the slides were incubated in a
staining solution consisting of 57 ml Fluorescein-FragEL TdT
labeling reaction mix and 3 ml TdT enzyme solution for 1.5 hr
at 37C in a humidified atmosphere. The cells were washed
three times in TBS for 1 min at room temperature, and the
slides were eventually mounted onto a microscope slide with a
drop of mounting medium. Images were acquired with a
motorized Leica DM6000 B microscope equipped with a
DFC350FX camera (Leica, Mannheim, Germany) at 3200,
and the signal intensity was analyzed in ImageJ.
RESULTS
Effects of Oxaliplatin and OA-GcMAF Treatment
on the Viability and Density of BV-2 and C13NJ
cells
BV-2 and C13NJ microglial cell viability was eval-
uated by the WST-8 assay after 24 hr of treatment with
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oxaliplatin at different concentrations. As shown in
Figure 1A,C, the viability of BV-2 and C13NJ cells
decreased with increasing oxaliplatin concentration, as
expected. Significant differences (P< 0.05) were observed
when BV-2 cells were treated with oxaliplatin concentra-
tions of 1, 10, and 100 mM compared with untreated con-
trol cells (Fig. 1A). For C13NJ cell viability, significant
differences (P< 0.05) were observed for oxaliplatin con-
centrations of 100 mM, 500 mM, and 1 mM compared
with untreated control cells (Fig. 1C). These results con-
firm the known cytotoxicity of oxaliplatin and demon-
strate that human microglial cells are somehow more
resistant than murine cells to oxaliplatin-induced damage.
The significant decrease of oxaliplatin-induced cell
viability in both microglial cell lines was associated with a
significant decrease of cell density, as evaluated by light
microscopy. Cell density variations were then quantified in
the appropriate software and expressed as cell surface/mm2.
Consistent with the results obtained from the cell viability
assay, BV-2 cell density was significantly decreased
(P< 0.05) when the cells were treated with 10 and 100
mM oxaliplatin, whereas no significant difference was
observed for the lowest concentration of oxaliplatin
(1 mM; Fig. 1B). C13NJ cell density variations fully con-
firmed the data obtained from the cell viability assay, dem-
onstrating that a significant decrease in cell density
occurred for all oxaliplatin concentrations tested (Fig. 1D).
These results demonstrate that the decrease of total
cell dehydrogenase activity was effectively the result of a
decrease in the number of viable cells rather than a non-
specific decrease of cell metabolic activity. Furthermore,
the data obtained both from the cell viability assay and
from the morphological analysis indicated that the most
appropriate concentration of oxaliplatin to induce reversi-
ble cell damage on microglial cells was 10 mM for BV-2
cells and 100 mM for C13NJ cells. Therefore, these oxali-
platin concentrations were used in the experiments
described below.
When the BV-2 and C13NJ microglial cells were
treated for 48 hr with OA-GcMAF (800 pM), a
Fig. 1. Viability and density of BV-2 and C13NJ cells after treatment
with oxaliplatin. A,C: Cell viability was evaluated by the WST-8
assay. Histograms show the decrease of BV-2 (A) and C13NJ (C)
metabolic activity after 24 hr of oxaliplatin treatment at different con-
centrations. B,D: Cell density was evaluated by light microscopy after
H&E staining and quantified in ImageJ. Images show the decrease of
cell density of BV-2 (B) and C13NJ (D) cells after 24 hr of oxaliplatin
treatment at different concentrations. Histograms show the mean area
occupied by BV-2 (B) and C13NJ (D) surfaces in five different fields
(1 mm2) on each coverslip. Two coverslips were blindly counted for
each experimental point. Results are mean6 SEM for two replicates;
each experiment was performed three times. O.D., optical density;
OXA, oxaliplatin. *P< 0.05 vs. control. Scale bars5 100 mm.
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significant increase (P< 0.05) in cell viability was
observed compared with control cells (untreated and cul-
tured for the same time in the same media but without
OA-GcMAF; Fig. 2A,B). However, the decrease in cell
viability induced by oxaliplatin at the appropriate concen-
tration (10 mM for BV-2 and 100 mM for C13NJ) was
not reversed by pretreatment with OA-GcMAF. In this
case, the presence of OA-GcMAF, added 24 hr before
the treatment with oxaliplatin and still present during the
treatment with oxaliplatin, did not restore BV-2 or
C13NJ cell viability (Fig. 2A,B). These results demon-
strate that, despite their differential resistance to
oxaliplatin-induced damage, the murine and the human
cell lines show an analogous behavior to OA-GcMAF in
terms of cell viability.
Treatment of BV-2 and C13NJ Cells with
Oxaliplatin and OA-GcMAF: Study of
cAMP and VEGF Expression
Oxaliplatin treatment of BV-2 (10 mM) and C13NJ
(100 mM) cells induced a significant decrease in cAMP
levels after 25 min (Fig. 3A,B). These results were consist-
ent with the damage inflicted by oxaliplatin and cell via-
bility measurements. OA-GcMAF (800 pM) did not
significantly affect microglial cAMP levels in BV-2 or
C13NJ cells compared with untreated control cells
(Fig. 3A,B). When BV-2 and C13NJ cells were treated
with OA-GcMAF and then with oxaliplatin, no signifi-
cant variations in cAMP levels were observed compared
with the oxaliplatin-reduced cAMP levels (Fig. 3A,B).
These results suggest that the cellular damage inflicted by
Fig. 2. Viability of BV-2 and C13NJ cells after treatment with oxali-
platin and OA-GcMAF. A,B: OA-GcMAF treatment of BV-2 and
C13NJ cells for 48 hr induces significant changes in cell viability.
Oxaliplatin treatment, as expected, significantly decreases cell viability
compared with controls. OA-GcMAF pretreatment for 24 hr before
adding oxaliplatin does not significantly affect cell viability compared
with oxaliplatin treatment alone. Results are mean6 SEM for three
replicates. Each experiment was performed three times. O.D., optical
density; OXA, oxaliplatin; OA-GcMAF, oleic acid Gc-protein-
derived macrophage-activating factor. *P< 0.05 vs. control.
Fig. 3. cAMP levels from BV-2 and C13NJ cells after treatment with oxaliplatin and OA-GcMAF.
A,B: cAMP levels, evaluated by ELISA assay, were measured after 25 min of 800 pM OA-GcMAF
treatment, suggesting that OA-GcMAF does not activate the cAMP signal transduction pathway in
BV-2 or C13NJ cells. In contrast, oxaliplatin induces a significant decrease of cAMP, which is not
affected by the presence of OA-GcMAF. OXA, oxaliplatin; OA-GcMAF, oleic acid Gc-protein-
derived macrophage-activating factor.
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oxaliplatin was not reversed by pretreatment with OA-
GcMAF, even at the level of cAMP second messenger
formation.
In addition, because microglial cells produce VEGF,
and considering the role of the cAMP/VEGF signaling
pathway in microglia (Licht and Keshet, 2013; Krause
et al., 2014), we investigated the variations of VEGF
expression in BV-2 and in C13NJ microglial cells after
treatment with oxaliplatin for 24 hr and/or with OA-
GcMAF for 48 hr. The results showed that the treatment
of BV-2 cells and C13NJ cells with 800 pM OA-GcMAF
did not induce a significant change in VEGF expression,
as demonstrated by Western blot and densitometric analy-
sis (Fig. 4A,C). Quantitative evaluation by RT-qPCR
confirmed that OA-GcMAF did not induce any signifi-
cant modification in the levels of VEGF mRNA in BV-2
or in C13NJ cells (Fig. 4B,D). Furthermore, VEGF
expression was not significantly modified by oxaliplatin
treatment or a combination of oxaliplatin/OA-GcMAF
in BV-2 or C13NJ cells compared with control cells.
These results were further confirmed by RT-qPCR anal-
ysis (Fig. 4B,D). Taken together, these results indicate
that OA-GcMAF did not activate the cAMP/VEGF sig-
naling pathway in BV-2 and C13NJ cells, nor did it
counteract the oxaliplatin-induced effects. Therefore,
these results are consistent with the cAMP levels in
response to stimuli in both cell lines, confirming the
observation that the cAMP/VEGF signal transduction
pathway was not affected by oxaliplatin and/or OA-
GcMAF treatment.
B7-2 Expression in BV-2 and C13NJ Cells
Following Oxaliplatin and OA-GcMAF Treatment
To assess whether the increase of cell viability
induced by OA-GcMAF treatment was the result of
microglial activation, we investigated the expression of
B7-2, a protein that is upregulated in activated microglia
and is involved in breaking the synaptic contacts of
impaired neurons to allow nerve regeneration and neuri-
togenesis (De Simone et al., 1995). B7-2 expression was
evaluated by Western blot analysis, and the images were
densitometrically quantified in BV-2 and in C13NJ
microglial cells after oxaliplatin and/or OA-GcMAF
Fig. 4. VEGF expression in BV-2 and C13NJ cells after oxaliplatin
and OA-GcMAF treatment. Western blot, densitometric analysis, and
RT-qPCR. A,C: VEGF expression, evaluated by Western blot analy-
sis and quantified in ImageJ, did not change after BV-2 and C13NJ
cells were treated with 800 pM OA-GcMAF for 48 hr, with oxalipla-
tin alone for 24 hr, or with a combination of both stimuli. B,D:
Evaluation of VEGF mRNA by RT-qPCR confirmed the data
obtained by Western blot analysis and densitometric quantification.
No significant differences are observed in BV-2 or C13NJ cells after
OA-GcMAF and oxaliplatin treatment (alone or in combination).
Results are mean6 SEM for two replicates. Each experiment was
performed three times. OXA, oxaliplatin; OA-GcMAF, oleic acid
Gc-protein-derived macrophage activating factor.
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treatment. Oxaliplatin treatment of BV-2 and of C13NJ
microglial cells at concentrations of 10 mM and 100 mM,
respectively, induced a significant increase in B7-2
expression in comparison with untreated control cells
(Fig. 5A,C), as expected in the case of toxicants (Di
Cesare Mannelli et al., 2013b). After 48 hr of treatment
with OA-GcMAF alone, the expression of B7-2 was sig-
nificantly increased in both BV-2 and C13NJ microglial
cells compared with untreated control cells (Fig. 5A,C).
The expression of B7-2 in BV-2 and C13NJ cells was
further increased with a combination of oxaliplatin and
OA-GcMAF (Fig. 5A,C). However, it is notable that,
although both oxaliplatin and OA-GcMAF induced an
increase in B7-2 expression, the former is a known toxi-
cant (as demonstrated in the literature and confirmed by
the results from cell viability assay), whereas the latter
stimulated cell viability in both murine and human cells.
These results suggest that OA-GcMAF positively affects
basal activation of microglial cells in the presence of a
steady-state microenvironment. Furthermore, these data
indicate that OA-GcMAF could make the microglial
cells more responsive to activation by a toxicant, i.e.,
oxaliplatin. We hypothesize that the damage inflicted by
oxaliplatin leads to a strong microglial activation in the
presence of OA-GcMAF, in turn leading to faster clear-
ance of dying cells and cellular debris. Evaluation of B7-
2 mRNA by RT-qPCR in BV-2 cells provided some
interesting information (Fig. 5B). In the presence of OA-
GcMAF (alone or in combination with oxaliplatin), BV-
2 cells expressed higher levels of B7-2 mRNA compared
with untreated control cells. This result confirms the data
obtained from Western blot analysis and densitometry
(Fig. 5A). However, when BV-2 cells were treated with
oxaliplatin alone, the level of B7-2 mRNA was signifi-
cantly lower compared with the control cells, whereas
the level of B7-2 protein was higher (Fig. 5A). This
apparently odd result can be explained because oxalipla-
tin interacts not only with DNA but also with mRNA
and possibly interferes with its integrity (Becker et al.,
2014).
Fig. 5. B7-2 expression in BV-2 and C13NJ cells after oxaliplatin and
OA-GcMAF treatment. Western blot, densitometric analysis, and
RT-qPCR. A,C: After OA-GcMAF treatment, B7-2 expression,
evaluated by Western blot analysis and quantified in ImageJ, was sig-
nificantly increased compared with untreated control cells. Oxaliplatin
treatment alone in BV-2 and C13NJ cells induced, as expected, a sig-
nificant increase of B7-2 expression, which is further increased when
OA-GcMAF and oxaliplatin act together (*P< 0.05). B: Evaluation
of B7-2 mRNA by RT-qPCR in BV-2 cells confirms the OA-
GcMAF-induced increase in expression, both alone and in the pres-
ence of oxaliplatin. However, B7-2 mRNA and protein expression
disagree when the cells are treated with oxaliplatin alone. Evaluation
of B7-2 mRNA in C13NJ cells is not shown because no signal was
detected by RT-qPCR. Results are mean6 SEM for two replicates.
Each experiment was performed three times. OXA, oxaliplatin; OA-
GcMAF, oleic acid Gc-protein-derived macrophage activating factor.
*P< 0.05 vs. control.
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RT-qPCR evaluation in C13NJ cells showed unde-
tectable expression of B7-2 mRNA at all of the experi-
mental points (data not shown). This result is confirmed
by data available in the literature demonstrating that the
expressions of the B7-2 protein and its mRNA are unre-
lated (The Human Protein Atlas; http://www.proteinat-
las.org/ENSG00000114013-CD86/tissue).
To rule out the possibility that microglial activation
induced by OA-GcMAF could result in an increase of
microglial cells, a potentially detrimental phenomenon,
cell counts were performed with standard trypan blue
staining 24 and 48 hr after OA-GcMAF treatment. As
shown in Figure 6A, there was no significant increase in
cell numbers when BV-2 cells were treated with OA-
GcMAF for 24 hr. Conversely, after 48 hr of OA-
GcMAF treatment, a significant decrease in BV-2 cell
numbers was observed (Fig. 6A). OA-GcMAF treatment
of C13NJ cells for 24 or 48 hr resulted in a significant
decrease in cell numbers (Fig. 6B). These results suggest
that OA-GcMAF could increase microglial activation
(with higher expression of B7-2 protein) without leading
to a concomitant and potentially harmful increase in cell
numbers. These results also confirm that the behavior of
murine and human microglial cells, in terms of activation,
is essentially the same, albeit not identical.
Morphology and Apoptosis of BV-2/SH-SY5Y
and C13NJ/SH-SY5Y Cocultures Following
Oxaliplatin and OA-GcMAF Treatment
Data from cocultures of murine microglial cells and
human neurons (BV-2/SH-SY5Y) show that the mor-
phology and the interactions between neurons and micro-
glial cells were deeply affected by 10 mM oxaliplatin
treatment. As shown in Figure 7A, microglia–neuron
connections and neuron density were decreased after oxa-
liplatin treatment (Fig. 7Ab) compared with control
(Fig. 7Aa) and OA-GcMAF-treated cells (Fig. 7Ac). After
oxaliplatin treatment, debris (Fig. 7A, white arrows) and
numerous microglial cells (Fig. 7A, black arrowheads)
were closely contacting and surrounding the neurons
(Fig. 7Ab), suggesting a specific response of microglia to
the damage induced by the oxaliplatin-altered microen-
vironment (Wake et al., 2009). Microglia–neuron con-
nections (Fig. 7A, white arrowheads) and the regular
distribution of glia around the neurons were restored
when the cocultures were pretreated with OA-GcMAF
for 24 hr prior to oxaliplatin addition (Fig. 7Ad). How-
ever, the neuron density was still reduced because of the
toxic effect of oxaliplatin, and a large amount of debris
could still be detected around the cells.
To investigate and quantify the cell damage inflicted
by oxaliplatin and the protective effect of OA-GcMAF
further, a TUNEL assay was performed to analyze apo-
ptosis. As shown in Figure 7B, very few apoptotic cells
were detectable in control cells (Fig. 7Ba) or in cells
treated with OA-GcMAF (Fig. 7Bc), as expected for cell
“healthy” cultures. However, when the cells were treated
with 10 mM oxaliplatin (Fig. 7Bb), the number of apopto-
tic cells significantly increased; conversely, and in line
with the protective effect of OA-GcMAF, the number of
apoptotic cells was significantly reduced when the cocul-
tures were pretreated with OA-GcMAF for 24 hr before
adding oxaliplatin (Fig. 7Bd). Variations in apoptosis, as
observed by fluorescence microscopy, were then quanti-
fied in the appropriate software and expressed as cell sur-
face/mm2 (Fig. 7C). As shown by histograms, taking the
level of apoptosis in control cells to be 100%, oxaliplatin
increased the level of apoptosis by more than threefold.
When the cocultures were pretreated with OA-GcMAF
and then with oxaliplatin, the level of apoptosis was sig-
nificantly decreased compared with oxaliplatin treatment
alone.
Additionally, the data obtained from cocultures of
human microglial cells and human neurons (C13NJ/
SH-SY5Y) demonstrated that the cell morphology and
Fig. 6. BV-2 and C13NJ cell counts after OA-GcMAF treatment. A,B: BV-2 and C13NJ cell
counts by standard trypan blue staining. OA-GcMAF treatment for 24 and 48 hr is not associated
with an increase in the number of cells compared with controls. Results are mean6 SEM for five
replicates. Each experiment was performed three times. OA-GcMAF, oleic acid Gc-protein-derived
macrophage activating factor. *P< 0.05 vs. control.
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Fig. 7. BV-2/SH-SY5Y coculture morphology and apoptosis after
oxaliplatin and OA-GcMAF treatment. A: Cell morphology. a:
Untreated control cells. Neurons show a typical triangular body, evi-
dent nucleus, wide cytoplasm, and several long cytoplasmic elonga-
tions. Microglia are represented primarily by deeply stained rounded
cells with thin elongations. Elongations arising from the glial cells and
neurons form an intricate net linking the microglia and neurons to
each other. b: Ten micromolar oxaliplatin-treated cells. Most of the
cellular connections are deeply damaged, and only a few neurons are
present. Much debris (white arrows), a clear sign of cell degeneration,
is present. Numerous glial cells are distributed along and around the
few damaged neurons (black arrowheads). c: OA-GcMAF-treated
cells. No significant differences are observed in the microglia or neu-
rons when the coculture is treated with OA-GcMAF compared with
untreated control cells. No debris or clusters of damaged cells can be
observed. Numerous cell connections are present. d: OA-GcMAF
and oxaliplatin-treated cells. Proper connections between neurons and
glia (white arrowheads) are restored compared with oxaliplatin treat-
ment alone. Neuron density remains decreased because of the toxic
effects of oxaliplatin. B: TUNEL assay. In control cells (a) as well as
in cells treated with OA-GcMAF (c), only a basal, low level of apo-
ptosis is detectable. When the cells are treated with 10 mM oxaliplatin
(b), a significant increase in the number of apoptotic cells is observed;
apoptosis is significantly reduced when cocultures are pretreated with
OA-GcMAF for 24 hr before adding oxaliplatin (d). In this case, only
a few clusters of damaged cells are still present. 3200. Variations of
apoptosis were quantified in the appropriate software and expressed as
cell surface/mm2 (C). Results are mean6 SEM for five replicates.
Each experiment was performed three times. *P< 0.05 vs. control;
**P< 0.05 vs. oxaliplatin. Scale bars5 100 mm.
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Fig. 8. C13NJ/SH-SY5Y coculture morphology and apoptosis after
oxaliplatin and OA-GcMAF treatment. A: Cell morphology. a:
Untreated control cells. Neurons show a typical triangular body, evi-
dent nucleus, wide cytoplasm, and several long cytoplasmic elonga-
tions. Microglia are represented primarily by deeply stained cells with
different shape and size, sometimes forming clusters. Elongations aris-
ing from the glial cells and neurons form an intricate net linking the
microglia and neurons to each other. b: Ten micromolar oxaliplatin-
treated cells. Most of the cellular connections are lost or deeply dam-
aged, and only a few neurons are present. Much debris (black arrows),
a clear sign of cell degeneration, is present. c: OA-GcMAF-treated
cells. No significant differences are observed in the microglia or neu-
rons when the coculture is treated with OA-GcMAF compared with
untreated control cells. Numerous and well-defined cell connections
are present. d: OA-GcMAF- and oxaliplatin-treated cells. Cell con-
nections are increased (white arrowheads) compared with oxaliplatin
treatment alone. Neuron density remains decreased because of the
toxic effects of oxaliplatin, and some debris is still present. B: TUNEL
assay. In control cells (a) as well as in cells treated with OA-GcMAF
(c), only a basal, low level of apoptosis is detectable. When the cells
are treated with 10 mM oxaliplatin (b), a significant increase in the
number of apoptotic cells is observed; cell death is significantly
reduced when the cocultures are pretreated with OA-GcMAF for 24
hr before adding oxaliplatin (d). 3200. Variations of apoptosis were
quantified in the appropriate software and expressed as cell surface/
mm2 (C). Results are mean6 SEM for five replicates. Each experi-
ment was performed three times. *P< 0.05 vs. control; **P< 0.05
vs. oxaliplatin. Scale bars5 100 mm.
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interactions between neurons and microglial cells were
deeply damaged by the treatment with oxaliplatin. Simi-
larly to the previous results, OA-GcMAF was able to
reverse the damage inflicted by oxaliplatin (Fig. 8A).
Although the oxaliplatin concentration used for all the
experiments involving the C13NJ cells was 100 mM, a 10
mM concentration was used for the coculture experiments
because the neurons are more sensitive to oxaliplatin than
C13NJ cells.
We also observed a decrease in microglia–neuron
connections in C13NJ/SH-SY5Y cocultures after oxali-
platin treatment (Fig. 8Ab). Many cells (both neurons and
microglia) showed severe morphological modifications
and large amounts of debris (Fig. 8A, black arrows)
around the cells compared with the untreated control cells
(Fig. 8Aa). OA-GcMAF treatment for 24 hr prior to add-
ing oxaliplatin restored the normal microglia–neuron
connections (Fig. 8A, white arrowheads) and partially
restored the cell morphology (Fig. 8Ad). Treatment with
OA-GcMAF alone (Fig. 8Ac) did not induce significant
changes compared with the control cells.
Apoptosis was evaluated by TUNEL assay also on
C13NJ/SH-SY5Y cocultures. As shown in Figure 8B,
only a few apoptotic cells were detectable in control cells
(Fig. 8Ba) or cells treated with OA-GcMAF (Fig. 8Bc).
When the cocultures were treated with 10 mM oxaliplatin
(Fig. 8Bb), a significant increase in the number of apopto-
tic cells was observed. However, apoptosis was signifi-
cantly reduced when the cocultures were pretreated with
OA-GcMAF for 24 hr before adding oxaliplatin (Fig.
8Bd). Variations of apoptosis, observed by fluorescent
microscopy, were then quantified in the appropriate soft-
ware and expressed as cell surface/mm2 (Fig. 8C). As
shown by histograms, an approximately threefold increase
in apoptosis was observed after oxaliplatin treatment com-
pared with control cells. When the cocultures were pre-
treated with OA-GcMAF and then with oxaliplatin, the
level of apoptosis significantly decreased (P< 0.05) com-
pared with oxaliplatin alone. Taken together, these results
confirm that both the oxaliplatin-induced damage and the
protective effects of OA-GcMAF were essentially the
same in murine microglia/human neuron and human
microglia/human neuron cocultures.
DISCUSSION
Several microglial cell lines are available and are currently
used for research studies in addition to primary microglia.
Microglial cultures were first described early in the 1930s,
but the use of cultures to study microglial function
occurred only after methods for obtaining and culturing
large amounts of microglial cells had been developed and
improved. The increased yield and homogeneity of cul-
tured cells allows for increased data output in a shorter
time compared with in vivo experiments. Furthermore,
in vitro cultures present a beneficial tool for studying the
activation state, releasable factors, and other crucial com-
ponents that characterize microglia, which cannot be suf-
ficiently examined in vivo. Among the different models
of microglial cell lines used to study neuroinflammatory
and neurodegenerative diseases are immortalized micro-
glial cell cultures from human, rat, and mouse that are ret-
rovirally or nonretrovirally transformed. Some of these
culture models share relevant similarities, but at the same
time they are separated by significant differences, depend-
ing on their origin, methods of culturing, functional
aspects, and availability. One of the most extensively used
microglia models is the retrovirally immortalized murine
BV-2 cell line. This cell line is currently available on the
market, is easily cultured, and is morphologically well
characterized. However, the main criticism regarding
BV-2 cells is that the cell line has been immortalized from
mouse cortex and represents a cell line that is appropriate
for murine rather than human studies. Therefore, there
are also human cell lines because humans are one of the
most important models. Some human immortalized
microglial cell lines exist, among them HMO6 and
C13NJ cells. Even if the characteristics of these cell lines
make them appropriate for investigating human inflam-
matory processes and neurodegenerative diseases, they are
rarely used because of the difficulty in obtaining and cul-
turing them and the fact that little is known about their
morphological properties. This study demonstrates that
human C13NJ and rat BV-2 microglia cell lines share
common signaling mechanisms when treated with a neu-
rotoxic chemotherapeutic agent, oxaliplatin, and with
OA-GcMAF, a molecule able to reverse oxaliplatin-
induced neuronal damage and induce beneficial microglia
activation.
At variance with its effects on neurons (Morucci
et al., 2014), OA-GcMAF does not appear to restore the
decrease of cell viability induced by oxaliplatin, and, con-
sistently, it does not increase cAMP or induce the expres-
sion of VEGF in BV-2 or C13NJ cells. This study also
demonstrates that the expression of B7-2, a specific pro-
tein marker of microglial cell activation, increases in BV-
2 and C13NJ cells in the presence of oxaliplatin-induced
cell damage as well as after OA-GcMAF treatment alone.
When BV-2 and C13NJ cells were triggered with oxali-
platin in the presence of OA-GcMAF, the expression of
B7-2 protein further increased. It is noteworthy that OA-
GcMAF treatment was associated with an increase in cell
viability as well as an increased expression of B7-2 protein
without a concomitant increase of the cell number, lend-
ing credit to the hypothesis that OA-GcMAF-stimulated
microglial cells contribute to overall neuroprotective
effects by scavenging oxaliplatin-induced damage without
nonspecific gliosis. This hypothesis is consistent with the
notion that microglial cell activation is directly engaged in
processes involved in restoring normal signaling and pro-
tecting against neurotoxicity (Milligan and Watkins,
2009).
Cocultures are a dynamic system for studying
microglial interaction with neurons because microglia are
able to establish wide-ranging interactions with the
microenvironment. In agreement with these notions and
considering the active role of microglia in preserving neu-
ronal function and in restoring and/or preserving
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neuronal viability, we evaluated the interactions of mouse
and human microglia with human neurons. Data from
BV-2/SH-SY5Y as well as from C13NJ/SH-SY5Y
cocultures showed that cellular morphology, interactions
between neurons and microglial cells, and level of apo-
ptosis were deeply affected by oxaliplatin treatment. The
presence of OA-GcMAF significantly reduced the level
of oxaliplatin-induced morphological alterations and apo-
ptosis in both cocultures, leading us to hypothesize an
active role for OA-GcMAF in counteracting the toxic
effects of oxaliplatin on neurons through microglial
activation.
We observed an interesting RT-qPCR result from
our data, even though it was not strictly related to the tar-
get of the present study. In fact, although VEGF expres-
sion in microglia cells evaluated by Western blotting and
densitometric analysis was superimposable to the expres-
sion of VEGF mRNA measured by RT-qPCR, the
results for the B7-2 marker were somewhat unexpected.
In this case, the expression of the B7-2 protein in BV-2
cells was only partially confirmed by RT-qPCR, and in
C13NJ cells no B7-2 mRNA was detected. These results
can be explained by considering that most reports on
mRNA and protein find only a weak correlation between
the abundances of these two classes of biological mole-
cules (Maier et al., 2009). The correlation between
mRNA and protein abundance depends on various bio-
logical and technical factors. Transcription and translation
processes, mRNA decay, micro-RNAs, and a longer
half-life of proteins are only some of the factors involved
in this lack of correlation, supporting the fact that mRNA
levels cannot be used to evaluate and predict the corre-
sponding protein levels (Wang et al., 2008). In conclu-
sion, because the BV-2 and the C13NJ cell lines (alone
and cocultured with human neurons) show analogous
responses to oxaliplatin and OA-GcMAF in terms of
cAMP/VEGF signal transduction pathway, cell viability,
activation, and protein expression, we hypothesize that
the murine BV-2 cell line is an excellent and validated
experimental model for human microglial cells that is
inexpensive and easy to culture and retrieve.
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